Eculizumab for atypical hemolytic-uremic syndrome

N Engl J Med. 2009 Jan 29;360(5):542-4. doi: 10.1056/NEJMc0808527.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Complement C3b Inactivator Proteins / genetics
  • Complement C5 / antagonists & inhibitors*
  • Complement Factor H / genetics*
  • Female
  • Hemolytic-Uremic Syndrome / complications
  • Hemolytic-Uremic Syndrome / drug therapy*
  • Hemolytic-Uremic Syndrome / genetics
  • Humans
  • Immunologic Factors / therapeutic use*
  • Kidney / pathology
  • Kidney Failure, Chronic / etiology
  • Kidney Failure, Chronic / surgery
  • Kidney Transplantation
  • Mutation, Missense
  • Recurrence
  • Sequence Deletion

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • CFHR1 protein, human
  • Complement C3b Inactivator Proteins
  • Complement C5
  • Immunologic Factors
  • Complement Factor H
  • eculizumab